INIT Stock Overview
A clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Initiator Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 6.80 |
| 52 Week High | SEK 11.75 |
| 52 Week Low | SEK 6.30 |
| Beta | 0.55 |
| 1 Month Change | 5.43% |
| 3 Month Change | -6.21% |
| 1 Year Change | -26.57% |
| 3 Year Change | -16.87% |
| 5 Year Change | -16.87% |
| Change since IPO | 17.24% |
Recent News & Updates
Recent updates
We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn
May 31
Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?
Feb 27Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?
May 20Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?
Jan 06We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn
Oct 26We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate
Jun 12Shareholder Returns
| INIT | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -4.2% | 1.2% | -2.7% |
| 1Y | -26.6% | 13.8% | 4.6% |
Return vs Industry: INIT underperformed the Swedish Biotechs industry which returned 13.8% over the past year.
Return vs Market: INIT underperformed the Swedish Market which returned 4.6% over the past year.
Price Volatility
| INIT volatility | |
|---|---|
| INIT Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: INIT has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: INIT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 3 | Claus Olesen | www.initiatorpharma.com |
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes IPED2015, a drug candidate which is in clinical phase 2a for the treatment of organic erectile dysfunction; IP2018, a monoamine reuptake inhibitor completed Phase IIa for the treatment of psychogenic erectile dysfunction primarily targeting the serotonin followed by the dopamine system; and IPTN2021, a Phase 1 clinical drug program targeting an orphan drug indication in severe neuropathic pain, and trigeminal neuralgia. The company also developing IP2017, a proprietary triple reuptake inhibitor; and IP2016, a preclinical development for the treatment of depression.
Initiator Pharma A/S Fundamentals Summary
| INIT fundamental statistics | |
|---|---|
| Market cap | SEK 382.46m |
| Earnings (TTM) | -SEK 16.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-23.3x
P/E RatioIs INIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INIT income statement (TTM) | |
|---|---|
| Revenue | DKK 0 |
| Cost of Revenue | DKK 11.80m |
| Gross Profit | -DKK 11.80m |
| Other Expenses | -DKK 1.15m |
| Earnings | -DKK 10.65m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 28, 2025
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did INIT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 07:51 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Initiator Pharma A/S is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Klas Palin | Penser Access |
| Kevin Sule | Redeye |